Insulin sensitiser drugs

Bibliography

• POLONSKY KS, STURIS J, BELL GI: Non-insulindependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N. Engl. J. Med. (1996) 334:777–783.
   PubMed Web of Science ®Google Scholar
• NOLAN JJ, OLEFSKY JM: Insulin action and insulinresistance in NIDDM. In: Clinical Research in Diabetes and Obesity: Volume Ii Diabetes and Obesity. Draznin B, Rizza R, (Eds.) Humana Press, UK (1997):137–158.
   Google Scholar
• DEFRONZO RA, BONADONNA RC, FERRANNINI E:Pathogenesis of NIDDM: A balanced overview. Diabetologia (1992) 35:389–397.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Role of insulin resistance in humandisease. Diabetes (1988) 37:1595–1607.
   PubMed Web of Science ®Google Scholar
• FUJITA T, SUGIYAMA Y, TAKETOMI S et al.: Reduction of insulin resistance in obese and/or diabetic animals by 3[-4-(1-methykyclohexylmethoxy)benzylj-thiazolidin e-2,4-dione (ADD-3870, U63287, ciglitazone), a new antidiabetic agent. Diabetes (1983) 32:804–810.
   PubMed Web of Science ®Google Scholar
• FUJIWARA T, YOSHIOKA S, YOSHIOKA T, USHIYAMA I, HORIKOSHI H: Characterisation of a new antidiabetic agent, CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes (1988) 37:1549–1588.
   PubMed Web of Science ®Google Scholar
• IKEDA H, TAKETOMI S, SUGIYAMA Y et al.: Effects of Pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arz-Forsch/Drug Res. (1990) 40:156–162.
   PubMed Web of Science ®Google Scholar
• STEVENSON RW, HUTSON NJ, KRUPP MN et al.: Actionsof novel antidiabetic agent englitazone in hypergly-caemic hyperinsulinaemic ob/ob mice. Diabetes (1990) 39(10):1218–27.
   PubMed Web of Science ®Google Scholar
• OAKES ND, KENNEDY CJ, JENKINS AB, LAYBULF DR,CHRISHOLM DJ, KRAEGEN EW: A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes (1994) 43:1203–1210.
   PubMed Web of Science ®Google Scholar
• CHAIKEN RL, ECKERT-NORTON M, PASMANTIER R et al.:Metabolic effects of darg,litazone, an insulin sensitizer, in NIDDM subjects. Diabetologia (1995) 38:1307–1312.
   PubMed Web of Science ®Google Scholar
• US DEPARTMENT OF HEALTH AND HUMAN SERVICES:Rezulin to be withdrawn from the market. March 21, 2000.
   Google Scholar
• LEHMANN JM, MOORE LB, SMITH-OLIVER TA, WILKISONWO, WILLSON TM, KLIEWER SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxi-some proliferator-activated receptor y (PPARy). J. Biol. Chem. (1995) 270(22):12953–12956.
   PubMed Web of Science ®Google Scholar
• BRAISSANT O, FOUFELLE F, SCOTTO C et al : Differentialexpression of peroxisome proliferator-activated receptors (PPARS): tissue distribution of PPAR-alpha, -beta, -gamma in the adult rat. Endocrinology (1996) 137(1):354–66.
   PubMed Web of Science ®Google Scholar
• NOLTE RT, WISELY GB, WESTIN S et al.: Ligand bindingand co-activator assembly of the peroxisome proliferator-activated receptor gamma. Nature (1998) 395:137–143.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, SUNDSETH SS, JONES SA et al.: Fatty acidsand eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. USA (1997) 94(9):4318–4323.
   PubMed Web of Science ®Google Scholar
• KELLER H, DREYER C, MEDIN J, MAFOUDI A, OZATO K,WAHLI W: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA (1993) 90:2160–2164.
   PubMed Web of Science ®Google Scholar
• LEMBERGER T, DESVERGNE B, WAHLI W: Peroxisomeproliferator activated receptors: A nuclear receptor signalling pathway in lipid physiology. Ann. Rev. Cell Dev. Biol. (1996) 12:353–363.
   Google Scholar
• GELMAN L, ZHOU G, FAJAS L, RASPE E, FRUCHART JC,AUWERX J: p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J. Biol. Chem. (1999) 274(12):7681–7688.
   PubMed Web of Science ®Google Scholar
• ZHU Y, QI C, CALANDRA C, RAO MS, REDDY J: Cloningand identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator -activated receptor y. Gene E. (1996) 6:185–195.
   PubMed Web of Science ®Google Scholar
• ZHU Y, KAN L, QI C et al.: Isolation and characterizationof peroxisome proliferator-activated receptor (PPAR) interacting protein (PIUP) a coactivator for PPAR. J Biol. Chem. (2000) 275(18):13510–13516.
   PubMed Web of Science ®Google Scholar
• ZHU Y, QI C, JAIN M, RAO S, REDDY JK: Isolation andcharacterization of PBP, a protein that interacts with peroxisime proliferator-activated receptor. J. Biol. Chem. (1997) 272(41):25500–25506.
   PubMed Web of Science ®Google Scholar
• SCHOONJANS K, PEINADO-ONSURBE J, LEFEBVRE AM et al PPARalpha and PPARgarnma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. (1996) 15(19):5336–5348.
   PubMed Web of Science ®Google Scholar
• TONTONOZ P, GRAVES RA, BUDAVARI AT et al.: Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res. (1994) 22(25):5628–5634.
   PubMed Web of Science ®Google Scholar
• CASTELEIN H, GULICK T, DECLERCQ PE, MANNAERTS GP,MOORE DD, BAES MI: The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J. Biol. Chem. (1994) 269(43):26754–26758.
   PubMed Web of Science ®Google Scholar
• SHIMAYA A, KUROSAKI E, SHIODUKA K, NAKANO R,SHIBASAKI M, SHIKAMA H: YM268 increases the glucose uptake, cell differentiation and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Horm. Metab. Res. (1998) 30(9):543–548.
   PubMed Web of Science ®Google Scholar
• DAY C: Thiazolidinediones: a new class of antidiabeticdrugs. Diabetic Med. (1999) 16:179–192.
   PubMed Web of Science ®Google Scholar
• MAGGS DG, BUCHANAN TA, BURANT CF et al.: Metaboliceffects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Int. Med. (1998) 128:176–185.
   PubMed Web of Science ®Google Scholar
• NOLAN JJ, LUDVIK B, BEERDSEN P, JOYCE M, OLEFSKY J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. (1994) 331:1188–1193.
   PubMed Web of Science ®Google Scholar
• INZUCCHI SE, MAGGS DG, SPOLLETT GR et al.: Efficacy and metabolic effects of metformin and troglitazone in Type II diabetes mellitus. N. Engl. J. Med. (1998) 338:867–872.
   PubMed Web of Science ®Google Scholar
• SAGHIZADEH M, ONG JM, GARVEY WT, HENRY RR, KERNPA: The expression of tumor necrosis factor alpha by human muscle. Relationship to insulin resistance. JC/ (1996) 97(4):1111–1116.
   Google Scholar
• HOFMANN. C, LORENZ K, BRAITHWAITE SS et al : Alteredgene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology(1994) 134(1):264–270.
   PubMed Web of Science ®Google Scholar
• MURASE K, ODAKA H, SUZUKI M, TAYUKI N, IKEDA H:Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia (1998) 41:257–264.
   PubMed Web of Science ®Google Scholar
• SOUZA SC, YAMAMOTO M, FRANCIOSA M, LIEN P ANDGREENBERG AS: BRL 49653 blocks the lipolytic actions of tumour necrosis factor-alpha: A potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes (1998) 47:691–695.
   PubMed Web of Science ®Google Scholar
• FUKUZAWA M, SATOH J, Q1ANG X et al.: Inhibition oftumor necrosis factor-a with anti-diabetic agents. Diab. Res. Clin. Pract. (1999) 43:147–154.
   Google Scholar
• MILES PDG, ROMEO OM, HIGO K, COHEN A, RAFAAT K,OLEFSKY JM: TNF-a induced insulin resistance in vivo and its prevention by troglitazone. Diabetes (1997) 46:1678–1683.
   PubMed Web of Science ®Google Scholar
• BERN MM: Platelet function in diabetes mellitus.Diabetes (1978) 27:342–350.
   PubMed Web of Science ®Google Scholar
• SHECHTER M, MERZ CN, PAUL-LABRADOR MJ, KAUL S:Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J. Am. Coll. Cardiol. (2000) 35(2):300–307.
   PubMed Web of Science ®Google Scholar
• ISHIZUKA T, ITAYA S, WADA H et al.: Differential effectof the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes (1998) 47:1494–1500.
   PubMed Web of Science ®Google Scholar
• SONG J, WALSH MF, IGWE R et al.: Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca 2+ currents and not endothelial nitric oxide production. Diabetes (1997) 46:659–664.
   PubMed Web of Science ®Google Scholar
• ASANO M, NAKAJIMA T, IWASAWA K et al.: Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br. J. Pharmacol. (1999) 128(3):673–683.
   PubMed Web of Science ®Google Scholar
• WALKER AB, NADERALI EK, CHATTINGTON PD et al.:Differential vasoactive effects of the insulin sensitizers Rosiglitazone (BRL 49653) and Troglitazone on human small arteries in vitro. Diabetes (1998) 47:810–814.
   PubMed Web of Science ®Google Scholar
• WALKER AB, CHATTINGTON PD, BUCKINGHAM. RE, WILLIAMS G: The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes (1999) 47(7):1448–1453.
   Google Scholar
• LEE MK, MILES PDG, KHOURSHEED M, GAO KM, MOOSAAR, OLEFSKY JM: Metabolic effects of troglitazone on fat induced insulin resistance in the rat. Diabetes (1994) 43:1435–1439.
   PubMed Web of Science ®Google Scholar
• YOSHIOKA S, NISHIMO H, SHIRAKI T et al.: Antihyper-tensive effects of CS-045 treatment in obese Zucker rats. Metabolism (1993) 42:75–80.
   PubMed Web of Science ®Google Scholar
• PERSHADSINGH HA, SZOLLOSI, BENSON S, HYUN WC, FEUERSTERIN BG, KURTZ TW: Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension (1993) 21:1020–1023.
   PubMed Web of Science ®Google Scholar
• SUNG BH, IZZO JL Jr, DANDONA P, WILSON MF: Vasodi-latory effects of troglitazone improve blood pressure at rest and during mental stress in Type 2 diabetes mellitus. Hypertension (1999) 34(1):83–88.
   PubMed Web of Science ®Google Scholar
• ST. JOHN SUTTON M, DOLE JF, RAPPAPORT EB: Rosigllta-zone does not adversely affect cardiac structure or function in patients with Type 2 diabetes. Diabetes (1999) 48(S1)A102:0438.
   Google Scholar
• IMANO E, KANDA T, NAKATANI Y et al.: Effect of troglita-zone on microalbunainuria in patients with incipient diabetic nephropathy. Diabetes Care (1998) 21(12):2135–2139.
   PubMed Web of Science ®Google Scholar
• FREED MI, WESTON WM, VIBERTI G: Rosigjitazone reduces urinary albumin excretion in Type 2 diabetes. Diabetologia (1999) (S1):866.
   Google Scholar
• YOUNG PG, CAWTHORNE MA, COYLE PJ et al.: Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell surface GLUT4 as measured by photoaffinity labeling. Diabetes (1995) 44:1087–1092.
   Google Scholar
• SUGIYAMA Y, SHIMURA Y, IKEDA H: Effects of pioglita-zone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arz. Forschl. Drug Res. (1990) 40:436–440.
   PubMed Web of Science ®Google Scholar
• MATHISEN A, GEERLOF J, HOUSER V: The effect of pioglitazone on glucose control and lipid profile in patients with Type 2 diabetes. Diabetes (1999) 48(S1):0441.
   Google Scholar
• MATHISEN A, GEERLOF J, HOUSER V: The effect ofpioglitazone on glucose control and lipid profile in patients with Type 2 diabetes. Diabetes (1999) 48(S1):0441.
   Google Scholar
• FONSECA VA, VALIQUETT TR, HUANG SM et al.: Troglita-zone Monotherapy Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus: A randomized, controlled study. J. Clin. Endocrinol. Metab. (1998) 83:3169–3175.
   PubMed Web of Science ®Google Scholar
• RASKIN P, RAPPAPORT EB, COLE ST, YAN Y, PATWARDHAN R, FREED MI: Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type 2 diabetes. Diabetologia (2000) 43(3):278–284.
   PubMed Web of Science ®Google Scholar
• TACK CJJ, SMITS P, DEMACKER PNM STALENHOEF AFH: Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care (1998) 21:796–799.
   PubMed Web of Science ®Google Scholar
• MORI Y, MURAKAWA Y, OKADA K et al.: Effect of trogli-tazone on body fat distribution in Type 2 diabetic subjects. Diabetes Care (1999) 6:908–912.
   Google Scholar
• KAWAI T, TAKEI I, OGUMA Y et al.: Effects of troglita-zone on fat distribution in the treatment of male Type 2 diabetes. Metabolism (1999) 48(9):1102–1107.
   PubMed Web of Science ®Google Scholar
• KUMAR S, BOULTON AJM, BECK-NIELSEN H et al.: Trogli-tazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia (1996) 39:701–709.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, KOSAKA K, KUZUYA T et al.: Effects oftrog,litazone, a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care (1996) 19:151–156.
   PubMed Web of Science ®Google Scholar
• LEBOWITZ HE, PATEL J, DOLE J, PATWARDHAN R: Rosiglitazone monotherapy has significant glucose effect in Type 2 diabetic patients. Diabetologia (1998) 41(S1):A238, 922.
   Google Scholar
• GRUNBERGER G, WESTON WM, PATWARDHAN R, RAPPAPORT EB: Rosiglitazone once or twice daily improves glycaemic control in patients with Type 2 diabetes. Diabetes (1999) 48:A102, 0439.
   Google Scholar
• NOLAN JJ, JONES NP, PATWARDHAN R, DEACON LF:Once-daily rosig,litazone is effective in the treatment of Type 2 diabetes mellitus. Diabetes (2000) (In press).
   Google Scholar
• BEEBE K, PATEL J: Rosiglitazone is effective and welltolerated in patients 65 years with Type 2 diabetes. Diabetes (1999) 48:A111:0479.
   Google Scholar
• KREIDER M, MILLER E, PATEL J: Rosiglitazone is safe andwell tolerated as monotherapy or combination therapy in patients with Type 2 diabetes mellitus. Diabetes (1999) 48:A117:0506.
   Google Scholar
• SCHNEIDER R, LESSEM J, LEKICH R: Pioglitazone iseffective in the treatment of patients with Type 2 diabetes. Diabetes (1999) 48:A109:0469.
   PubMedGoogle Scholar
• IWAMOTO Y, KOSAKA K, KUZUYA T, AKANUMA Y, SHIGETA Y, KANEKO T: Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet. Med. (1996) 13:365–370.
   PubMed Web of Science ®Google Scholar
• BUYSSCHAERT M, BOBBIONI E, STARKIE M, FRITH L: Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Diabet. Med. (1999) 16:147–153.
   PubMed Web of Science ®Google Scholar
• HORTON ES, WHITEHOUSE F, GHAZI MN, VENABLE TC,WHITCOMB RW: Troglitazone in combination with sulphonylurea restores glycaemic control in patients with Type 2 diabetes. The trog,litazone study group. Diabetes Care (1998) 21(9):1462–1469.
   PubMed Web of Science ®Google Scholar
• BANDO Y, USHIOGI Y, OKAFUJI K, TOYA D, TANAKA N,FUJISAWA M: Troglitazone combination therapy in obese Type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. J. Int. Med. Res. (1999) 2:53–64.
   Google Scholar
• RASKIN P, KENNEDY F, WOO V, JAIN R, BOSS AH: Amulticenter, randomized study of the therapeutic effect of repaglinide combined with trog,litazone in subjects with Type 2 diabetes. Diabetes (1999) 48(S1):A107:0463.
   Google Scholar
• YALE JF, VALIQUETT TR, FOYT H: Troglitazone efficacyand safety in combination with sulphonylurea and Metformin as triple therapy. Diabetes (1 9 99) 48(S1):A118:0510.
   Google Scholar
• WOLFFENBUTTEL BHR, GOMIS R, SQUATRITO S, JONESNP, PATWARDHAN RN: Addition of low-dose rosig,lita-zone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabetic Med. (2000) 17:40–47.
   PubMed Web of Science ®Google Scholar
• FONSECA V, ROSENSTOCK J, PATWARDHAN R, SALZMANA: Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus.JAMA (2000) 283(13):1695–1702.
   Google Scholar
• SCHNEIDER R, EGAN J, HOUSER V: Combination therapy with pioglitazone and sulphonylurea in patients with Type 2 diabetes. Diabetes (1999) 48(S1):A106:0458.
   Google Scholar
• EGAN J, RUBIN C, MATHISEN A: Combination therapywith pioglitazone and metformin in patients with Type 2 diabetes. Diabetes (1999) 48(S1):A117:0504.
   Google Scholar
• MATHISEN A, EGAN J, SCHNEIDER R: The effect of combination therapy with pioglitazone and sulphony-lurea on the lipid profile in patients with Type 2 diabetes. Diabetes (1999) 48(S1):A106:0457.
   Google Scholar
• EGAN J, RUBIN C, MATHISEN A: Adding pioglitazone tometformin therapy improves the lipid profile in patients with Type 2 diabetes. Diabetes (1999) 48(S1):A106:0459.
   Google Scholar
• SCHWARTZ S, RASKIN P, FONSECA V, GRAVELINE JF, FOR THE TROGLITAZONE AND EXOGENOUS INSULIN STUDY GROUP: Effect of troglitazone in insulin-treated patients with Type 2 diabetes. N. Engl. J. Med. (1998) 338:861–866.
   PubMed Web of Science ®Google Scholar
• BUSE JB, GUMBINER B, MATHIAS NP et al.: Troglitazone use in insulin-treated Type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care (1998) 21:1455–1461.
   PubMed Web of Science ®Google Scholar
• LETTER L, ROSS S, HALLE JP, TOMOVICI A: Efficacy andsafety of troglitazone in Type 2 diabetic patients inadequately controlled on insulin therapy. Diabetes (1999) 48(51):A115:0495.
   Google Scholar
• RASKIN P, DOLE JF, RAPPAPORT E: Rosiglitazoneimproves glycaemic control in poorly controlled insulin treated Type 2 diabetes. Diabetes (1999) 48(S1):A94:0404.
   Google Scholar
• RUBIN C, EGAN J, SCHNEIDER R: Combination therapy with pioglitazone and insulin in patients with Type 2 diabetes. Diabetes (1999) 48(S1):A110:0474.
   Google Scholar
• GITLIN N, NEIL J, SPURR CL et al.: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Int. Med. (1998) 129:36–38.
   PubMed Web of Science ®Google Scholar
• NEUSCHWANDER-TETRI BA, ISLEY WL, OKI JC et al.: Troglitazone-induced hepatic failure leading to liver transplantation. Ann. Int. Med. (1998) 129:38–41.
   PubMed Web of Science ®Google Scholar
• WATKINS PB, WHITCOMB RW: Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. (1998) 338:916–917.
   PubMed Web of Science ®Google Scholar
• SALZMAN A: Rosiglitazone is not associated with hepatotoxicity. Diabetologia (1999) 42(S1):A3, 8.
   Google Scholar
• AL-SALMAN J, ARJOMAND H, KEMP DG, MITTAL M: Hepatocellular injury in a patient receiving rosiglita-zone. Ann. Intern. Med. (2000) 132(2):121–124.
   PubMed Web of Science ®Google Scholar
• FORMAN LM, SIMMONS DA, DIAMOND RH: Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. (2000) 132(2):118–121.
   PubMed Web of Science ®Google Scholar
• WILLIAMS GD, DELDAR A, JORDAN WH, GRIES C, LONG CG, DIMARCH RD: Subchronic toxicity of the thiazolidinedione Tanabe-174 (LY282449) in the rat and the dog. Diabetes (1993) 42:186A.
   Google Scholar
• GHAZZI M, PEREZ J, ANTONUCCI T, DRISCOLL J, HUANG S, FAJA BW: The Troglitazone Study Group and Whitcomb R: Cardiac and g,lycemic benefits of troglita-zone treatment in NIDDM. Diabetes (1997) 46:433–439.
   PubMed Web of Science ®Google Scholar
• LOT CM, YOUNG M, RANDINITIS E, VASSOS A, KOUP JR:Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. (1999) 37(2):91–104.
   PubMed Web of Science ®Google Scholar
• THOMPSON KA, MILLER AK, INGLIS AML, PATTERSON S, JORKASKY D, FREED MI: Rosiglitazone does not markedly alter CYP3A4-mediated drug metabolism. Diabetologia (1999) 42(S1):A227:852.
   Google Scholar
• ANTONUCCI T, WHITCOMB R, MCLAIN R, LOCKWOOD D: Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care (1997) 20:188–193.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ K, PETERS R, KJOS S et al.: Effect of troglita-zone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes (1996) 45:1572–1579.
   PubMed Web of Science ®Google Scholar
• THE DIABETES PREVENTION PROGRAM. RESEARCH GROUP: The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of Type 2 diabetes. Diabetes Care (1999) 22(4):623–634.
   Google Scholar
• EHRMANN. DA, SCHNEIDER DJ, SOBEL BE et al.: Troglita-zone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endo. Met. (1997) 82(7):2108–2116.
   Google Scholar
• DUNAIF A, SCOTT D, FINEGOOD D, QUINTANA B, WHITCOMB R: The insulin-sensitizing agent troglita-zone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endo. Met. (1996) 81(9):3299–306.
   PubMed Web of Science ®Google Scholar
• KASHIWAGI K, NAGAFUCHI S, SEKIGUCHI N et al.: Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy. Eur. Neurol. (1999) 41(3):171–172.
   PubMed Web of Science ®Google Scholar
• TAKINO H, OGHUNI S, UOTANI S: Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome. Diabetes Res. Clin. Pract. (1994).
   Google Scholar
• ELKIND-HIRSCH KE, MCWILLIAMS RB: Pregnancy after treatment with the insulin-sensitizing agent troglita-zone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. Fertil. Steril. (1999) May 71(5):943–947.
   Google Scholar
• YAMAKITA T, ISHII T, MORI T et al.: Troglitazone amelio-rates insulin resistance in a diabetic patient with Prader-Willi syndrome. Diabetes Res. Clin. Pract (1998) 42(3):205–208.
   PubMed Web of Science ®Google Scholar
• SUNAYAMA S, WATANABE Y, OHMURA H et al : Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atheroscle-rosis (1999) 146(1):187–193.
   PubMed Web of Science ®Google Scholar
• COLLINS AR, MEEHAN WP, HOWARD-TAYLOR TR et al.: Troglitazone attenuates atherosclerosis in low density lipoprotein receptor-/- mice fed a high fat diet. Diabetes (1999) 48(51):A30:0129.
   Google Scholar
• DUBOIS RN, GUPTA R, BROCKMAN J, REDDY BS, KRAKOW SL, LAZAR MA: The nuclear eicosanoid receptor, PPAR gamma, is aberrantly expressed in colonic cancers. Carcinogenesis (1998) 19(1):49–53.
   PubMed Web of Science ®Google Scholar
• KUBOTA T, KOSHIZUKA K, WILLIAMSON EA et al Ligand for peroxisome proliferator receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 58(15):3344–3352.
   PubMed Web of Science ®Google Scholar
• MUELLER E, SARRAF P, TONTONOZ P et al.: Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell (1998) 1(3):465–470.
   PubMed Web of Science ®Google Scholar
• TONTONEZ P, SINGER S, FORMAN BM et al.: Terminal differentiations of human liposarcoma cells induced by ligands for peroxisome proliferator activated receptor y and the retinoid X receptor. Proc. Natl. Acad. Sci. USA (1997) 94:237–241.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, FLETCHER CD, MUELLER E et al Induction of solid tumor differentiation by the peroxisime proliferator activated receptor-gamma ligand trog,litazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA (1999) 96(7):3951–3956.
   PubMed Web of Science ®Google Scholar
• KITAMURA S, MIYAZAKI Y, SHINOMURA Y, KONDO S, KANAYAMA S, MATSUZAWA Y: Peroxisome proliferator activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J. Cancer Res. (1999) 90(1):75–80.
   PubMedGoogle Scholar